Arnab Chakravarti, MD
College of Medicine
Cancer ● Glioblastoma ● Glioma ● Brain Cancer ● Prostatic Cancer ● Neoplasm Metastasis ● Breast Cancer ● Neoplasm Invasiveness ● Lung Cancer
Arnab Chakravarti, MD, is the Max Morehouse Chair of Cancer Research at Ohio State, where he directs the Brain Tumor Program and chairs the Department of Radiation Oncology. A member of the OSUCCC – James Translational Therapeutics Program, he focuses on translational cancer research to identify novel biomarkers that are predictive of treatment efficacy and survival, and to uncover molecular and genetic mechanisms of treatment resistance to advance care of cancer patients.Under his leadership with the National Cancer Institute-supported Radiation Therapy and Oncology Group Brain Tumor/NRG Translational Research Subcommittee and Brain Tumor Committee, his team’s studies have defined the standard of care for patients with central nervous system (CNS) tumors. His lab was among the first to report that the dysregulation of PI3K/AKT signaling is associated with radiation resistance in glioblastomas. It also was the first to identify that dysregulation of PI3K signaling is significantly associated with adverse clinical outcomes in GBM patients. These findings led to some of the first clinical studies to combine radiotherapy with kinase inhibitors targeting this pathway. Dr. Chakravarti chairs the National Institute of Health Cancer Biomarkers Study Section (CBSS) and the board of the International Society of Neuro-Radiation Biology, and he is on the board of the Ohio Neuro-Oncology Consortium. He has published more than 120 articles in prestigious scientific and medical journals, including and The Journal of the American Medical Association. He also has presented throughout the world on the molecular and genetic mechanisms of treatment resistance in cancer.